Methods for treatment of atherosclerosis

Patent metadata

Field	Value
Publication number	US-10201585-B2
Application number	US-201314418809-A
Country	US
Kind code	B2
Filing date	Jul 31, 2013
Priority date	Aug 2, 2012
Publication date	Feb 12, 2019
Grant date	Feb 12, 2019

Abstract

Disclosed herein are methods and compositions for preventing or treating atherosclerosis in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide and, in some applications, a second active agent, to subjects in need thereof. The present technology relates to the treatment or prevention of atherosclerosis in mammals through the administration of a therapeutically effective amount of aromatic cationic peptides and, in some embodiments, a second active agent.

First claim

What is claimed is:

1. A method for delaying onset, ameliorating or eliminating statin side effects in a subject in need thereof, the method comprising administering simultaneously, separately or sequentially with the statin, an effective amount of a peptide D-Arg-2′6′-Dmt-Lys-Phe-NH 2 or a pharmaceutically acceptable salt thereof, wherein the statin side effect comprises one or more of rhabdomyolysis, kidney failure, diabetes, memory loss, and decreased coenzyme Q10 levels.

2. The method of claim 1 , wherein the statin is selected from the group consisting of: atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, pitavastatin, rosuvastatin, niacin extended-release/lovastatin, lovastatin extended-release, amlodipine, atorvastatin, rosuvastatin, sitagliptin/simvastatin, fluvastatin, fluvastatin extended-release, atorvastatin, pitavastatin, lovastatin, pravastatin, niacin extended-release/simvastatin, ezetimibe/simvastatin, and simvastatin.

3. The method of claim 1 , wherein the peptide and statin are administered sequentially in either order.

4. The method of claim 1 , wherein the pharmaceutically acceptable salt comprises acetate salt or trifluoroacetate salt.

5. The method of claim 1 , wherein the statin comprises rosuvastatin or atorvastatin.

Assignees

• Stealth Peptides Int Inc
• Stealth Biotherapeutics Corp

Inventors

• Wilson D Travis
• Bamberger Mark
• Blakey Brian

Classifications

• A61K31/404

  Indoles, e.g. pindolol · CPC title

• A61K31/215

  of carboxylic acids · CPC title

• A61K31/22

  of acyclic acids, e.g. pravastatin · CPC title

• A61K31/40

  having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title

• A61K31/505

  Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title